Praxis Precision Medicines' Phase 2 Ulixacaltamide Primary Endpoint Misses Statistical Significance
By Chris Wack Praxis Precision Medicines Inc. said Friday that topline results from its Phase 2 study evaluating the efficacy, safety and tolerability of ulixacaltamide for the treatment of... | March 3, 2023